Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Denifanstat

Generic Name: Denifanstat

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉N_₅O

CAS Number: 1399177-37-7

Unique Ingredient Identifier: 4GF95B2LZA

Overview

Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.

Background

Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Phase 3

Withdrawn

Posted: 2024/11/18

Sponsor:Sagimet Biosciences ...

ID:NCT06692283

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Phase 3

Withdrawn

Posted: 2024/09/19

Sponsor:Sagimet Biosciences ...

ID:NCT06594523

A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Phase 3

Active, not recruiting

Posted: 2024/02/08

Sponsor:Ascletis Pharmaceuti...

ID:NCT06248008

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Phase 3

Active, not recruiting

Posted: 2024/01/05

Sponsor:Ascletis Pharmaceuti...

ID:NCT06192264

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Recruiting

Posted: 2023/02/24

Sponsor:Weill Medical Colleg...

ID:NCT05743621

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025

2 months ago

DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.

FDA Clears IND for Sagimet's Novel FASN Inhibitor TVB-3567 for Acne Treatment

2 months ago

Sagimet Biosciences has received FDA clearance for its Investigational New Drug application for TVB-3567, a selective fatty acid synthase inhibitor targeting acne treatment.

Ascletis' Oral GLP-1RA ASC30 Shows Promising Results in Obesity Trials

4 months ago

Ascletis Pharma's ASC30, a novel oral GLP-1 receptor agonist, demonstrated dose-proportional pharmacokinetics and a long half-life of up to 60 hours in a Phase Ia study.

Liver Cirrhosis Clinical Trial Pipeline Gains Momentum

4 months ago

The liver cirrhosis treatment market is experiencing significant growth, driven by advancements in antiviral therapies and regenerative medicine. Over 30 companies are actively developing new treatments, with several promising therapies currently in clinical trials.

Sagimet Biosciences to Present Denifanstat's Anti-Fibrotic Effects in MASH at MASH-TAG 2025

5 months ago

Sagimet Biosciences will present on fatty acid synthase (FASN) inhibitors at the 9th Annual MASH-TAG Conference on January 10, 2025.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy